Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial
Immunovant saw its share prices soar to a new five-year high on Wednesday, as investors took heart from the stellar results of its clinical trial to study its drug candidate for hard-to-treat rheumatoid...






